NCT07116681Not yet recruitingEarly phase 1
Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension
The Acute Effects of Dry Powder Inhaled Treprostinil on Stroke Volume Augmentation and Dead Space Ventilation in Patients With Exercise-induced Pulmonary Hypertension
Source: ClinicalTrials.gov · Last updated 24 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate therapies for exercise induced pulmonary hypertension (EiPH). This is a condition that effects the blood vessels in the lungs and causes shortness of breath with activity. Currently, there are very limited treatment options for this condition. Inhaled treprostinil, also known as Tyvaso, is a medication used to treat other forms of lung disease and is safe and well tolerated. This study will measure the ability of Tyvaso to improve symptoms related to EiPH and improve performance on exercise testing.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- First submitted
- 7 Aug 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- University of California, San Diego
- NCT number
- NCT07116681
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 8
- From 1 Oct 2025 to the primary completion date, 1 Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability or unwillingness to discontinue any phosphodiesterase 5 inhibitors or other off-label
Other illness
- Diagnosis of pulmonary hypertension as defined by resting mean pulmonary arterial pressure of ≥ 20 mmHg, PVR \> 3
- Severe underlying chronic lung disease (e.g. COPD, interstitial lung disease)
- Chronic thromboembolic disease
- Known allergic reactions to inhaled treprostinil
Lab values
- Underlying chronic left ventricular disease (e.g. heart failure with reduced ejection fraction)
Other
- Pregnancy
- Acute infectious symptoms including fevers within the last week
- Inability to comply with study protocols
Who the study is looking for
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Persons, aged 18 years of older
- Established diagnosis of exercise induced pulmonary hypertension defined by the following:
- Invasive cardiopulmonary exercise testing demonstrating a mean pulmonary artery pressure to cardiac output (P/Q slope) greater than 3 mmHg/L/min
- Symptoms of exertional dyspnea
- Ability to perform non-invasive cardiopulmonary exercise testing, either on upright bicycle or treadmill
- If childbearing age, patient must agree to use of effective contraception during the trial
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.